Lilly Cuts Mid-stage Relaxin Study in Chronic Kidney Disease for ‘Lack of Foreseeable Clinical Benefit’

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an overlapping patient population.